Enhanced antitumor efficacy through sustained release of 5-fluorouracil from poly(trimethylene carbonate) membranes.

IF 4.4 2区 医学 Q1 PHARMACOLOGY & PHARMACY Frontiers in Pharmacology Pub Date : 2025-01-20 eCollection Date: 2024-01-01 DOI:10.3389/fphar.2024.1536764
Zongheng Wang, Zhipeng Hou, Shuguang Zhang, Shuangyi Ren, Liqun Yang, Qianshi Zhang
{"title":"Enhanced antitumor efficacy through sustained release of 5-fluorouracil from poly(trimethylene carbonate) membranes.","authors":"Zongheng Wang, Zhipeng Hou, Shuguang Zhang, Shuangyi Ren, Liqun Yang, Qianshi Zhang","doi":"10.3389/fphar.2024.1536764","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Cancer remains one of the deadliest diseases worldwide. 5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in clinical practice today, but its effectiveness is often hampered by rapid drug metabolism and systemic toxicity. To address these limitations, the development of novel drug delivery systems for sustained drug release is essential to improve therapeutic outcomes.</p><p><strong>Methods: </strong>This study aimed to develop a poly(trimethylene carbonate) (PTMC) membrane capable of sustained drug release of 5-FU to enhance its antitumor activity. The membranes were prepared using the solvent-casting method, and their comprehensive properties were characterized.</p><p><strong>Results and discussion: </strong>We evaluated the <i>in vitro</i> sustained release capability, as well as the biocompatibility and antitumor activity at both cellular and animal levels. The results demonstrated that the 5-FU-loaded PTMC membranes exhibited effective sustained release capabilities, superior biocompatibility, and enhanced antitumor effects compared to the 5-FU injections. These findings suggested that the 5-FU-loaded PTMC membranes hold great potential for application in cancer patients, offering benefits in chemotherapy treatment.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1536764"},"PeriodicalIF":4.4000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788581/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1536764","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Cancer remains one of the deadliest diseases worldwide. 5-Fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in clinical practice today, but its effectiveness is often hampered by rapid drug metabolism and systemic toxicity. To address these limitations, the development of novel drug delivery systems for sustained drug release is essential to improve therapeutic outcomes.

Methods: This study aimed to develop a poly(trimethylene carbonate) (PTMC) membrane capable of sustained drug release of 5-FU to enhance its antitumor activity. The membranes were prepared using the solvent-casting method, and their comprehensive properties were characterized.

Results and discussion: We evaluated the in vitro sustained release capability, as well as the biocompatibility and antitumor activity at both cellular and animal levels. The results demonstrated that the 5-FU-loaded PTMC membranes exhibited effective sustained release capabilities, superior biocompatibility, and enhanced antitumor effects compared to the 5-FU injections. These findings suggested that the 5-FU-loaded PTMC membranes hold great potential for application in cancer patients, offering benefits in chemotherapy treatment.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
期刊最新文献
Mechanistic insights into Rho/MRTF inhibition-induced apoptotic events and prevention of drug resistance in melanoma: implications for the involvement of pirin. Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways. Regulation of Hippo-YAP1/TAZ pathway in metabolic dysfunction-associated steatotic liver disease. Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis. Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1